Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

Table 3 Serious adverse events in the safety population

Serious adverse events	Safety population (n = 80)
Patient with ≥1 serious adverse event	14 (17.5)
Pneumonia	7 (8.8)
Lung infection	2 (2.5)
Cerebral infarction	2 (2.5)
Bronchitis	1 (1.3)
Bronchopneumonia	1 (1.3)
Lobar pneumonia	1 (1.3)
Cerebral ischemia	1 (1.3)
Neutropenia	1 (1.3)
Cardiac failure	1 (1.3)
Cataract	1 (1.3)
Spinal compression fracture	1 (1.3)
Electrolyte imbalance	1 (1.3)
Multiple myeloma^a	1 (1.3)
Deep vein thrombosis	1 (1.3)

All values n (%)
^aMultiple myeloma was considered an adverse event when the disease worsened, but did not meet the study criteria for progressive disease

ISSN: 1471-2407